



Quantifying Reductions in *Plasmodium falciparum* Infectivity to Mosquitos: A Sample Size Calculator to Inform Clinical Trials on Transmission-Reducing Interventions

Jordache Ramjith^{1,2†}, Manon Alkema^{1†}, John Bradley³, Alassane Dicko⁴, Chris Drakeley³, Will Stone³ and Teun Bousema^{1*}

OPEN ACCESS

Edited by:

Takafumi Tsuboi,
Ehime University, Japan

Reviewed by:

Robert Sinden,
Imperial College London,
United Kingdom
Kazutoyo Miura,
National Institute of Allergy and
Infectious Diseases (NIH),
United States

*Correspondence:

Teun Bousema
teun.bousema@radboudumc.nl

[†]These authors have contributed
equally to this work and share
first authorship

Specialty section:

This article was submitted to
Parasite Immunology,
a section of the journal
Frontiers in Immunology

Received: 18 March 2022

Accepted: 10 May 2022

Published: 03 June 2022

Citation:

Ramjith J, Alkema M, Bradley J,
Dicko A, Drakeley C, Stone W and
Bousema T (2022) Quantifying
Reductions in *Plasmodium falciparum*
Infectivity to Mosquitos: A Sample Size
Calculator to Inform Clinical Trials on
Transmission-Reducing Interventions.
Front. Immunol. 13:899615.
doi: 10.3389/fimmu.2022.899615

¹ Radboud Institute for Molecular Life Sciences, Department of Medical Microbiology, Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, Netherlands, ² Department for Health Evidence, Biostatistics Research Group, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, Netherlands, ³ Medical Research Council (MRC) International Statistics and Epidemiology Group, London School of Hygiene and Tropical Medicine, London, United Kingdom, ⁴ Malaria Research and Training Centre, Faculty of Pharmacy and Faculty of Medicine and Dentistry, University of Science, Techniques and Technologies of Bamako, Bamako, Mali

Malaria transmission depends on the presence of mature *Plasmodium* transmission stages (gametocytes) that may render blood-feeding *Anopheles* mosquitos infectious. Transmission-blocking antimalarial drugs and vaccines can prevent transmission by reducing gametocyte densities or infectivity to mosquitos. Mosquito infection outcomes are thereby informative biological endpoints of clinical trials with transmission blocking interventions. Nevertheless, trials are often primarily designed to determine intervention safety; transmission blocking efficacy is difficult to incorporate in sample size considerations due to variation in infection outcomes and considerable inter-study variation. Here, we use clinical trial data from studies in malaria naive and naturally exposed study participants to present an online sample size calculator tool. This sample size calculator allows studies to be powered to detect reductions in the proportion of infected mosquitos or infection burden (oocyst density) in mosquitos. The utility of this online tool is illustrated using trial data with transmission blocking malaria drugs.

Keywords: malaria, transmission, gametocyte, anopheles, mosquito, elimination, trial, oocyst

INTRODUCTION

Despite considerable improvements in access to efficacious antimalarial treatment and increased uptake of preventive strategies such as insecticide treated bed nets and indoor residual spraying, malaria is still responsible for over 2 million infections and approximately 627,000 deaths each year (1). The spread of resistance against antimalarial drugs (1) further highlights the need for additional tools in the fight against malaria. Tools that reduce the efficient transmission of malaria are considered particularly useful (2). Malaria transmission to mosquitos is initiated in the human host,

when a small proportion of asexual parasites differentiate into gametocytes, the sexual reproductive forms of the parasite. When the human host is bitten by a female *Anopheles* mosquito and gametocytes are taken up with the bloodmeal, gametes are formed. Sexual reproduction starts when male gametes fertilize female gametes to form zygotes that transform into motile ookinetes that penetrate the mosquito midgut wall to form an oocyst. The presence of oocysts is typically used as evidence for successful transmission to mosquitos. After approximately 8-12 days, sporozoites are released from the oocyst and colonize the salivary glands of the mosquito, thereby rendering it infectious upon its next bite.

Transmission blocking drugs can clear or sterilize gametocytes (3–5); transmission blocking vaccines are typically designed to elicit antibodies against surface antigens of *Plasmodium* gamete [e.g. Pfs230, Pfs48/45 (6)], zygote or ookinete forms [Pfs25 (7)] or mosquito midgut antigens [AnAPN1 (8)] and thereby prevent parasite development in mosquitos. Recently, monoclonal antibodies against gamete antigens have also been proposed as transmission-reducing tools by passive immunization (9, 10).

The ultimate public health endpoint of these transmission blocking interventions is a reduction in the force of infection and thereby the incidence of malaria infection in a population (11). However, studies with these public health endpoints are complex in design, expensive and logistically challenging to implement, typically involving cluster-randomized or stepped wedge designs. Early phase testing of transmission blocking efficacy requires biological endpoints that more directly estimate of human-to-mosquito transmission. These early trials may involve naturally infected gametocyte carriers or individuals participating in controlled human malaria infection (CHMI) studies where gametocytes are induced (12–14). In both studies, mosquitos may be allowed to feed directly on the skin of parasite carriers or on a venous blood sample that is offered through a membrane (15); mosquitos can subsequently be assessed for infection status.

These functional assays allow samples from early phase clinical studies to be used for meaningful assessments of vaccine efficacy. Although there is considerable recent interest in the transition from oocyst to sporozoites, and whether this involves a developmental bottleneck (16–18), the majority of oocyst-infected mosquitos will become sporozoite-positive mosquitos (19) and until a minimum oocyst or sporozoite density is defined to render an infected mosquito infectious, the proportion of mosquitos that become infected is considered the most relevant measure of the transmissibility of naturally acquired infections. The transmission-blocking activity (TBA) of an intervention are defined as its ability to reduce the proportion of mosquitos that is infected. It is also possible that interventions do not completely prevent mosquito infection but reduce the infection burden in mosquitos (i.e. oocyst density). Transmission-reducing activity (TRA) is defined as the achieved reduction in oocyst density compared to controls (20). While studies in gametocyte carriers are typically designed to measure TBA, experiments that determine the ability of test samples to reduce the transmission of *in vitro* cultured gametocytes typically measure TRA. In standard

membrane feeding assays (SMFA), high densities of cultured *P. falciparum* gametocytes are offered to mosquitos in the presence of test and control samples. SMFA are optimized to achieve high oocyst densities in control mosquitos to maximize precision and reproducibility (21). Because of this high infection intensity in control mosquitos, even highly potent samples may not prevent oocyst formation completely and TRA is the common readout of SMFA (20).

Sample size estimates for transmission blocking efficacy outcomes are challenging. When candidate vaccines, drugs or monoclonal antibodies enter clinical testing, they are typically primarily evaluated for safety in small first-in-human trials (7) that are powered on outcomes other than efficacy outcomes. Transmission assays are inherently noisy and considerable between-site variation exists in the performance of mosquito assays. Two additional complicating factors are the negative binomial distribution of oocysts (22–24), which is especially relevant when using oocyst density as an outcome measure, and the strong correlation between mosquito observations from the same individual in studies with naturally infected gametocyte carriers. Despite these challenges, mosquito feeding assays offer opportunities to maximize informativeness of trials with transmission-blocking interventions. In this context, we describe a negative binomial mixed effects model for TRA endpoints and a mixed effects logistic regression for TBA endpoints. Using these models, we designed a calculator tool that allows i) power analysis for transmission blocking intervention trials based on both TRA or TBA efficacy endpoints by means of mosquito feeding assays, ii) statistical analysis of data to either determine reference values for the power analysis or to quantify TRA and TBA as study outcomes. The practical application of the calculator is demonstrated with two clinical datasets.

MATERIALS AND METHODS

The Statistical Models


In order to calculate empirical power to detect reduction in oocyst prevalence/proportion of infected mosquitos, we simulated transmission data to estimate the effects of different levels of Transmission Blocking Activity (TBA). These data contain a binary outcome (a mosquito can either be infected or not infected), therefore a mixed effects logistic regression model was used. For power calculations for studies with reduction of oocyst density as an endpoint, the negative binomial distribution of oocysts has to be taken into account. This distribution is required as the majority of oocysts is found in a small proportion of all mosquitos (22–24). Therefore, to calculate the empirical power to estimate the effect of different levels of Transmission Reducing Activity (TRA), a mixed effects negative binomial regression model was used. For both models, we used mixed effects models, meaning we modelled both fixed effects of TBA and TRA as well as random intercepts. Both logistic regression and negative binomial regression models assume that the data are independent. Violations in this assumption leads to underestimated standard errors and thus an increased

likelihood of false positive findings. Including random intercepts in the models, allows for the correlation between outcomes for mosquito samples from the same participant to be accounted for; which we refer to as the intra-cluster correlation. The random intercepts are used to allow participant-level variation in pre-intervention transmissibility, i.e. a participant-specific baseline proportion of infected mosquitoes (for TBA models) or participant-specific baseline geometric mean oocyst density (for TRA models). The mathematical details for the data simulation algorithm and the statistical models and tests are given in the **Supplementary Information**.

To estimate empirical power for TBA, the calculator relies on user specifications of i) baseline proportion infected mosquitoes, ii) anticipated TBA and iii) the intra-cluster correlation that is used to directly estimate the variance of the random effects. The value that is entered for baseline proportion of infected mosquitoes is ideally based on site-specific data from preceding (pilot) studies or, if unavailable, on best estimates from existing literature, taking

into account variation in gametocyte density in the study population (**Figure 1B**). The percentage of transmission inhibition that we expect the studied intervention to achieve, the anticipated TBA, can be estimated based on pre-clinical data. The intra-cluster correlation reflects the correlation of infection between mosquitoes fed on the same participant and is determined based on the variance of the intercepts in the pilot dataset. Thus likelihood of infection in mosquitoes fed from one sample is highly correlated when the intra-cluster correlation is close to 1, and independent when the intra-cluster correlation is 0.

Similarly, to estimate empirical power for TRA, the calculator relies on four user-defined specifications of: i) baseline geometric mean oocyst density, ii) anticipated TRA, iii) variance of the random intercepts, and iv) the dispersion parameter. The baseline geometric mean oocyst density, variance of the random effects and dispersion parameter can be calculated in the data analysis tool preferably using site-specific individual mosquito level data from preceding (pilot) studies. The anticipated TRA is user-defined and



can for example be based on pre-clinical data. The dispersion parameter in the negative binomial regression model controls over-dispersion – which is the case when the empirical variation in the data is larger than that predicted from the model. The dispersion parameter and random effects variance together control the extent of inter-cluster correlation, for which an estimate is displayed in the input panel of the power calculator.

Finally, for both power calculations, a user-specified level of significance and a testing threshold should be specified. For the levels of significance, one of two choices is possible, 0.025 or 0.05, of which 0.025 is often preferred for one-sided tests/superiority trials and applicable for most envisaged use scenarios where TBA or TRA is anticipated to exceed a certain threshold value. This threshold can be zero, when merely testing whether an intervention reduces transmission compared to the pre-intervention control condition; often it is more informative to demonstrate that TBA/TRA is significantly larger than a higher threshold, for instance a minimum TRA of 80% has historically been proposed to identify potent interventions for further development. It is relevant to realize that this threshold TBA or TRA value is different from the anticipated TBA/TRA value, the value that we expect and is typically higher than the threshold level we aim to compare it to.

Study Populations and Reference Values

In order to provide reference values to inform envisioned future transmission studies, two datasets from recent clinical trials with transmission endpoints were analyzed in the calculator. For oocyst prevalence data (i.e. the proportion of infected mosquitos), individual-level data from studies examining the impact of transmission-reducing antimalarial drugs were used (25). This exemplar dataset was selected to illustrate reductions in the proportion infected mosquitos (i.e. transmission blocking activity; TBA) following interventions. In this study, naturally infected gametocyte carriers were included and transmissibility to mosquitos was assessed before and after a drug intervention. Briefly, naturally infected gametocyte carriers with microscopically detectable *P. falciparum* gametocyte densities (>16 gametocytes/ μL) were recruited and treated with conventional artemisinin-combination therapy (a 3-day regimen administered by weight of 320mg dihydroartemisinin and 40 mg piperazine per tablet) alone or combined with low doses of gametocytocidal drugs (0.0625 mg/kg, 0.125mg/kg, 0.25 mg/kg 0.5 mg/kg of primaquine). Before and after initiation of treatment, venous blood was drawn and offered to locally reared mosquitos that were examined 7 days later for the presence of oocysts (binary outcome: absent/present) with on average 70.5 mosquitos dissected per blood sample. This key dataset was complemented with data of four independent trials (4, 25–27) that evaluated the transmission blocking efficacy of gametocytocidal drugs by means of direct membrane feeding assays in a single site in Ouelesseboungou, Mali. These additional data were used to examine variation in the proportion of infected mosquitos at baseline, prior to administration of any transmission blocking drugs. The number of gametocytes determined by microscopy at screening was used to demonstrate how parasitological enrolment criteria such as

gametocyte density influenced baseline infectivity and thereby the efficiency of TBA assessments.

For oocyst density data, we used standard membrane feeding assay (SMFA) results from a clinical trial NCT04238689 with a highly potent transmission blocking monoclonal antibody as reference dataset. The efficacy of the monoclonal antibody was studied in malaria-naïve study participants; their serum samples being offered to mosquitos in the presence of high densities of cultured *P. falciparum* NF54 gametocytes in the SMFA, rendering this reference appropriate to illustrate reductions in oocyst density as an outcome (i.e. transmission-reducing activity; TRA). This dataset included 20 subjects before administration of a transmission blocking monoclonal antibody and 10 subjects post administration who were selected to have partial TRA. On average 19.4 mosquitos were dissected with a median oocyst density of 42 in mosquitos fed on pre-intervention samples. Post-administration samples were selected where the mean TRA value was approximately 80% (median 77.1%, range 62.4–86.1%), a TRA value traditionally used as threshold to support further development of transmission-blocking interventions (28, 29). This dataset was complemented with 11 independent experiments performed for the abovementioned clinical trial (30) to examine variance in oocyst density for SMFA experiments conducted at the same site (Radboudumc, Nijmegen, the Netherlands). The only entry criterion for SMFA experiments was a proportion of infected mosquitos of >70%, a pre-defined quality control threshold (20).

All trials in Mali received ethics approval by the Ethics Committee of the Faculty of Medicine, Pharmacy, and Dentistry of the University of Science, Techniques, and Technologies of Bamako (Bamako, Mali), and the Research Ethics Committee of the London School of Hygiene & Tropical Medicine (London, UK). The trial in the Netherlands received approval from the Arnhem-Nijmegen Committee on Research Involving Humans.

Simulation Scenarios

To show a range of power calculations for TRA and TBA respectively, we allowed different combinations of parameter values for the data simulation and empirical power calculations. For both TBA/TRA we allowed sample sizes $n = (10, 20, 30, 40)$ for participants and $m = (20, 40, 60)$ for mosquitos, based on conventional group sizes (31–35). We used consensus thresholds of meaningful efficacy (24, 28, 29, 36) to define anticipated $TBA/TRA = (70\%, 80\%, 95\%)$ and thresholds for detecting TBA/TRA larger than $\tau = (50\%, 80\%, 90\%)$. Further, for TRA we considered baseline geometric mean oocyst densities of $\mu_0 = (20, 30, 45)$ (37) and for TBA we considered baseline proportion infected mosquitos of $p_0 = (10\%, 15\%, 25\%)$ based on a meta-analysis of membrane feeding experiments (38). For intra-cluster correlation we considered values of 0 for independence and 0.5 or 0.35 for TBA or TRA analyses, respectively, as motivated by the reference data. For TRA, the intra-cluster correlation depends on both variance of the random effects and the dispersion parameter, so to keep the results comparable, we used a fixed dispersion parameter as estimated by the data analysis and varied the

variance of the random effects to determine the intra-cluster correlation (0, 0.35). We only considered a significance level of 0.025, being interested in one-tailed testing whether TRA or TBA were larger than a pre-defined threshold. A significance level of 0.025 for a one-tailed test is essentially the equivalent of a significance level of 0.05 for a two-tailed test; the empirical power for a significance level of 0.05 is always larger.


Software

All data analysis was conducted using R4.1.1 (39), in RStudio (40) making use of the mgcv package (41, 42) for the analysis. Rshiny was used to develop the app (43). The app is currently hosted on https://bousema-lab.shinyapps.io/transmission_sample_size/.

RESULTS

First, we evaluated the variance in baseline proportion of infected mosquitos from four previous transmission blocking intervention trials. Mosquito infection prevalence prior to the intervention differed per study and varied from 14.2% – 17.4% when including non-infectious participants, or from 21.1% - 24.0% when including only infectious participants (Figure 1A). The proportion of infected mosquitos at baseline was strongly correlated with concurrent gametocyte density (Figure 1B). Whilst this association has repeatedly been described (44–47) and the current analysis was not intended to improve on such estimates, the association is of immediate relevance in designing studies and selecting the study population. The proportion infected mosquitos at baseline is highly dependent on eligibility criteria: e.g. when using a threshold of >50 gametocytes/ μL as selection criterion, the average proportion of

infected mosquitos at baseline was 25%, increasing to 35% when using a threshold of >100 gametocytes/ μL , and 44% for a threshold of >200 gametocytes/ μL . The shape of the association between gametocyte density and mosquito infection rates may vary between study sites and years (48). To inform the size of pilot experiments to determine site-specific baseline data on the proportion of infected mosquitos, we explored how precision in estimates of baseline infectivity and intra-cluster correlation depends on the size of the study population. For this, we used one study population [2014 study in Figure 1A (25)] to randomly select subjects from. The true proportion of infected mosquitos for the average participant in the entire population ($n=81$) was 17.0% (95% CI: 13.0%, 21.6%); the true intra-cluster correlation in the entire population was 0.52 (95% CI: 0.42, 0.61). The distribution of estimates of the baseline infectivity and the intra-cluster correlation for 100 simulations with sampling sizes of 10 to 75 participants are presented in Figures 2A, B, respectively. When taking 100 random samples of 40 participants, 84% of the estimations of baseline proportion of infected mosquitos were within the 95% CI of the complete dataset of 81 participants. With this same sampling size of 40 participants, 93% of the estimations for intra-cluster correlation were within the 95% CI of the complete dataset. Forty participants in pilot experiments may thus provide reasonably precise estimates of baseline parameters. We next performed power calculations using an anticipated TBA = 90%, a threshold TBA of 80%, number of participants = 20 and number of dissected mosquitos per sample = 30 and a significance level of 0.025. The power was 73% using the true reference parameters of the full dataset (i.e. baseline proportion of infected mosquitos = 17.0% and intra-cluster correlation = 0.52). For a sample size of 40, approximately half of the estimates for proportion infected and intra-cluster correlation led to an estimated power within the acceptable power range with 5% margin of error,



and approximately 80% were within the acceptable power range when the margin of error was increased to 10% (**Figure 2C**).

Similarly, variance in baseline oocyst density was evaluated using the SMFA outcomes of malaria-naïve control sera from 11 separate experiments. Despite experiments being conducted with the same parasite line (NF54) and mosquito species (*An. stephensi*) in the same laboratory, the mean oocyst density per mosquito was highly variable over the experiments and reached 6.5 – 44.6 oocysts/mosquito (**Figure 1C**). These findings illustrate the need for site-specific baseline parameters for sample size calculations and, for SMFA, adequate controls.

To demonstrate the utility of the tool for data analysis, data from a previous transmission blocking intervention trial using proportion of infected mosquitoes by membrane feeding as the primary outcome measure (25) were analyzed in the mixed-effects logistic regression model. For a trial with natural gametocyte carriers, the reduction in the proportion of infected mosquitoes (TBA) is the preferred outcome. TBA was estimated as a function of the baseline proportion of infected mosquitoes and the estimated odds ratio from the model. These estimates included individuals who were not infectious to mosquitoes. Prior to treatment, 18.5% (15/81) of the participants in this trial was non-infectious (25) and, including these individuals, the estimated proportion of infected mosquitoes for the average person prior to treatment was 17.0% (95% CI: 13.0%, 21.6%) (2014 study in **Figure 1A**). Based on previous demonstrations of

the potency of primaquine in preventing transmission (25, 49), we used the analysis tool to test whether transmission was reduced by at least 80% following primaquine treatment. In our exemplar dataset, the proportion of infected mosquitoes was reduced to 2.0% (95% CI: 1.2%, 3.2%) (**Figure 3A**). TBA was estimated at 88% (95% CI: 82.2%, 91.9%), significantly larger than the threshold of 80% ($p=0.0058$). The intra-cluster correlation was estimated to be 0.52.

Subsequently, we used the data analysis tool to compare two out of five intervention arms from the same trial. In the study arm receiving 0.125mg/kg of primaquine, the estimated proportion of infected mosquitoes for the average person was 11.0% prior to treatment, which was reduced to 1.6% after intervention. The TBA is estimated to be 85.88% (95% CI: 76.93%, 91.36%), not significantly higher than the threshold of 80% ($p=0.0824$). For the study arm receiving 0.5 mg/kg of primaquine, the estimated 12.7% of mosquitoes that was infected for the average person at baseline, was reduced to 0.8% post-intervention, resulting in a TBA of 94.0% (95% CI: 86.4%, 97.4%), significantly higher than the threshold of 80% ($p=0.0021$). TBA was not statistically significantly different between arms ($p=0.0793$). The intra-cluster correlation was estimated to be 0.47.

Informed by these reference values we used a baseline proportion of infected mosquitoes of 15% and an intra-cluster correlation of 0.5 to perform power calculations for envisioned future trials with transmission reducing interventions.




FIGURE 3 | Analyzing the proportion of infected mosquitoes and oocyst burden in mosquitoes using the app. Demonstration of the data analysis output from the app. **(A)** Analysis of changes in percentage of infected mosquitoes. Violin plots show the percentage of infected mosquitoes pre- and post-intervention as determined by mosquito feeding assays from natural gametocyte carriers in a transmission trial performed in Mali in 2014, in purple and yellow respectively. On average 70.5 mosquitoes were dissected per sample. **(B)** Analysis of changes in infection burden (oocyst density). Violin plots show oocyst density pre- and post-intervention from samples selected from a trial evaluating a transmission blocking monoclonal antibody in malaria naïve subjects by means of mosquito feeding experiments with cultured gametocytes, in purple and yellow respectively. On average 19.4 mosquitoes were dissected per sample. Boxes indicate median and IQR, whiskers indicate range, outliers are presented as dots and were defined as $>1.5 \times \text{IQR}$.

Alternatively, all trials with the same enrolment criteria (**Figure 1A**) could be used to inform reference values for an envisioned future trial; these values are provided in **Supplementary Table 1**. We used several different sample sizes of human participants ($n=10$, $n=20$, $n=30$, $n=40$), numbers of mosquitos dissected ($m=20$, $m=40$, $m=60$), anticipated TBA values (70%, 80%, 95%) that we expect the efficacy of our studied transmission blocking intervention will be, and threshold TBA values (>50%, >80%, >90%) that we wish to show the TBA of the studied intervention exceeds. One example of the output of the power calculator for such a power estimation is shown in **Figure 4**. We repeated simulations using a range of baseline proportion of infected mosquitos (10%, 15% and 25%), and an intra-cluster correlation of 0; results are shown in **Table 1**. Note that this table is based on parameters that are representative for the study site of the datasets analyzed in this paper, but different values for intra-cluster correlation and other baseline parameters may represent better the users' own study site and can be computed using the data analysis tool.

Similarly, we analyzed data of a recent trial using reductions in oocyst density (i.e. transmission reducing activity; TRA) by SMFA as

the endpoint (30) in the mixed-effects negative binomial regression model. The number of 41.3 oocysts per mosquito for the average person at baseline was reduced to 10.5 after intervention (**Figure 3B**), resulting in a TRA of 74.5% (95% CI: 71.3, 77.3), significantly higher than the threshold of 70% ($p=0.0035$). The standard deviation of the random intercepts was 0.393 and the dispersion parameter was estimated as 3.316 which were used to estimate an ICC of 0.35.

Next, we compared two of the intervention arms from the same trial in the analysis tool. For the first arm the number of 52.7 oocysts per mosquito for the average person at baseline was reduced to 20.2 after intervention, resulting in a TRA of 61.6% (95% CI: 55.0, 67.3), not higher than the threshold of 70% is ($p=0.9987$). For the second arm, the number of 35.9 oocysts per mosquito for the average person at baseline was reduced to 5.3 oocysts per mosquito after intervention, resulting in a TRA of 85.3%, significantly higher than the threshold of 70% ($p<0.001$). Estimates of TRA were significantly different between arms ($p<0.001$). The standard deviation of the random intercepts was 0.36 and the dispersion parameter was estimated as 3.358 which were used to estimate an ICC = 0.31.

Power calculations for envisioned future studies were performed using a number of 20, 30 or 45 oocysts per mosquito for the average




FIGURE 4 | Examples of TBA and TRA power estimations. Demonstration of power calculation output of the app. These are illustrated using density plots, where the y-axis indicates the kernel density estimates for the values on the x-axis, which is a smoothed version of the histogram. **(A)** Percentage of transmission blocking activity (TBA) across simulations. The dashed line shows the mean TBA across simulations; the red shaded area shows the distribution of TBA estimates in simulations. As an example, variables based on the data analysis of a transmission blocking intervention trial performed in Mali, 2014 were entered in the power calculator. Number of simulations: 200, Anticipated TBA: 90%, Threshold: 80%, Number of subjects: 20, Number of dissections per subject: 40, Baseline proportion infected: 17.02%, Intra-cluster correlation: 0.5, Level of significance: 0.025. **(B)** P-values across simulations, using the variables as described in **(A)**. Dashed line shows level of significance (0.025); the green shaded area shows the distribution of p-values across simulations. Estimated power is presented in the text box. **(C)** Percentage of transmission reducing activity (TRA) across simulations. Dashed line shows the mean TRA across simulations. As an example, variables based on the data analysis of a trial evaluating the TRA of a monoclonal antibody were entered in the power calculator. Number of simulations: 200, Anticipated TRA: 75%, Threshold: 70%, Number of subjects: 10, Number of dissections per subject: 20, Geometric mean number of oocysts for the average subject pre-treatment: 41.27, Anticipated standard deviation of the random intercepts: 0.393, Anticipated dispersion parameter 3.316, Intra-Cluster Correlation: 0.35, Level of significance: 0.025. **(D)** P-values across simulations, using the variables as described in **(C)**. Dashed line shows level of significance (0.025). Estimated power is presented in the text box.

TABLE 1 | Power for trials using reduction in proportion of infected mosquitos as functional outcome.

		ICC = 0									ICC = 0.5									
n	m	Anticipated TBA=70			Anticipated TBA=80			Anticipated TBA=95			Anticipated TBA=70			Anticipated TBA=80			Anticipated TBA=95			
		$\tau=50$	$\tau=80$	$\tau=90$	$\tau=50$	$\tau=80$	$\tau=90$	$\tau=50$	$\tau=80$	$\tau>90$	$\tau=50$	$\tau=80$	$\tau=90$	$\tau=50$	$\tau=80$	$\tau=90$	$\tau=50$	$\tau=80$	$\tau=90$	
$p_0 = 10\%$	10	20	17.5	0	0	30	0	0	48.5	0	0	18.5	0	0	36.5	0	0	29	1.5	0
		40	40	0.5	0	84.5	2.5	0	81	27.5	0	49	0	0	78.5	0	0	53.5	17.5	0
		60	52	0	0	89.5	4.5	0	91.5	71	0.5	65.5	0	0	91.5	0.5	0	64.5	38	1
	20	20	32	0	0	70	1.5	0	91.5	27.5	0	53	0	0	82.5	0.5	0	53.5	17.5	0
		40	66	0	0	99	2	0	96	87	14.5	86	0	0	99	3	0	76.5	65.5	4
		60	82.5	0	0	100	3	0	100	100	35	95.5	0.5	0	99.5	8	0	84.5	81	20
	30	20	30	0	0	90	0	0	100	79	0	67.5	0	0	96.5	1.5	0	78.5	60	1
		40	74	0	0	100	0	0	100	100	40.5	95.5	0	0	100	6	0	94	92	19.5
		60	92	0	0	100	0	0	100	100	48	99	0	0	100	7.5	0	97	97	52
	40	20	51	0	0	100	0	0	100	99	2.5	83.5	0	0	100	1.5	0	87	84	2
		40	99.5	0	0	100	0	0	100	100	66.5	100	0	0	100	7.5	0	96	96	50.5
		60	98.5	0	0	100	0	0	100	100	79.5	100	0	0	100	10	0	99	99	78
$p_0 = 15\%$	10	20	29	0	0	55	1	0	73.5	2.5	0	35	0	0	61	0.5	0	48	9	0
		40	58	0	0	92	5	0	94	63	0	65.5	0	0	90	1	0	72	46.5	1
		60	65	0	0	99.5	3.5	0	99	90	19.5	77.5	0	0	99	2.5	0	79.5	70	6.5
	20	20	42.5	0	0	89.5	7	0	96	61	0	73	0	0	95.5	3	0	70	55	3
		40	87.5	0	0	100	5	0	100	99	22	93.5	0	0	100	7	0	88	87	26
		60	92.5	0	0	100	6	0	100	100	40	99.5	0	0	100	10.5	0	93.5	93.5	53.5
	30	20	57.5	0	0	97.5	0	0	100	83	10.5	77	0	0	99.5	2	0	91	88.5	7.5
		40	98	0	0	100	1	0	100	100	37	100	0	0	100	9	0	97	97	56
		60	100	0	0	100	3.5	0	100	100	57	100	0	0	100	12.5	0	98	98	78
	40	20	71	0	0	100	0	0	100	96.5	23	91	0	0	100	2.5	0	96	95.5	21
		40	100	0	0	100	0	0	100	100	56.5	100	0	0	100	9.5	0	99	99	79
		60	100	0	0	100	0	0	100	100	82.5	100	0	0	100	14	0	100	100	92.5
$p_0 = 25\%$	10	20	39	0	0	87	3.5	0	95	55	0	51.5	0	0	91	1	0	71	35.5	0.5
		40	78.5	0	0	100	2.5	0	100	96.5	26	81.5	0	0	99.5	4.5	0	88.5	84	12.5
		60	88.5	0	0	100	7	0	100	100	41	88.5	0	0	100	7	0	90	89	32
	20	20	59	0	0	100	6.5	0	100	94	11.5	84	0	0	100	5	0	91.5	89.5	14.5
		40	94	0	0	100	5.5	0	100	100	40.5	96	0	0	100	10	0	97.5	97.5	63
		60	100	0	0	100	11.5	0	100	100	70.5	99	0	0	100	12	0	98.5	98.5	76.5
	30	20	80	0	0	100	0	0	100	100	18	94	0	0	100	3.5	0	98	98	40.5
		40	100	0	0	100	0	0	100	100	80.5	100	0	0	100	8	0	100	100	81
		60	100	0	0	100	1.5	0	100	100	92.5	100	0	0	100	12.5	0	100	100	87.5
	40	20	92	0	0	100	0	0	100	100	19	98.5	0	0	100	3	0	100	100	55
		40	100	0	0	100	0	0	100	100	97	100	0	0	100	10.5	0	100	100	93.5
		60	100	0	0	100	0	0	100	100	99	100	0	0	100	16.5	0	100	100	97.5

ICC, intra-cluster correlation; TBA, transmission blocking activity; n, number of participants; m, number of mosquitos dissected; p_0 baseline proportion of infected mosquitos; τ , the threshold at which we wish to test that the anticipated TBA exceeds.

person at baseline and an intra-cluster correlation of 0 or 0.35 using several variations in trial characteristics (number of participants, number of dissections per sample, TRA threshold, anticipated TRA) (Table 2). An example of the power calculator output is shown in Figure 4. The following general patterns can be derived and are in agreement with the literature (21): i) for both TBA and TRA, empirical power is highly dependent on site specific parameters: oocyst density or proportion of infected mosquitos at baseline and intra-cluster correlation; ii) power can be increased substantially by using higher number of dissected mosquitos per sample.

DISCUSSION

We present a mathematical framework to calculate power and analyze data in transmission blocking intervention studies using either TBA or TRA as the efficacy outcome. These methods are

made accessible in an online tool that allows users to perform their own analyses and power calculations in pre- and post-intervention comparisons as well as study designs that compare an intervention- to a control group.

After years of relative neglect, there is an increasing interest in the impact of novel antimalarial drugs on transmission (50–52) and transmission blocking vaccines (53). An important advantage of transmission-blocking interventions is that there are informative biological endpoints for efficacy (11) for which there have been efforts to qualify assays (54). However, the large number of variables in mosquito feeding assays complicates both analysis and power calculations for transmission blocking intervention studies. The anticipated transmission inhibition, number of participants, number of mosquitos, baseline gametocyte density, baseline proportion of infected mosquitos or oocyst density all affect the power in such trials. What adds to that complexity, is that there are site-specific conditions (38)

TABLE 2 | Power for trials using reduction in oocyst density as functional outcome.

		ICC= 0									ICC= 35										
n	m	Anticipated TRA=50			Anticipated TRA=70			Anticipated TRA=80			Anticipated TRA=50			Anticipated TRA=70			Anticipated TRA=80				
		τ =35	τ =40	τ =45	τ =55	τ =60	τ =65	τ =65	τ =70	τ =75	τ =35	τ =40	τ =45	τ =55	τ =60	τ =65	τ =65	τ =70	τ =75		
μ ₀ = 20	5	10	60.5	32	13.5	89	59.5	24.5	99	85.5	43.5	55.5	32.5	14.5	87.5	60	21.5	99.5	86	42	
		20	87.5	61	17.5	99.5	92	36.5	100	99	69	87	56.5	16	99.5	89.5	33	100	98	67.5	
		30	97.5	78	24	100	98	58.5	100	100	89.5	97	77.5	25	100	97.5	59.5	100	100	91	
	10	10	91.5	57	14.5	100	93	39.5	100	99.5	70	88.5	57.5	16.5	99.5	91	37.5	100	99	67	
		20	100	83	41	100	100	71	100	100	93	99	86	36	100	100	71	100	100	91	
		30	100	95.5	49	100	100	82.5	100	100	99.5	100	96	48	100	100	83.5	100	100	100	
	20	10	100	94	26.5	100	100	70.5	100	100	96.5	100	92	31.5	100	100	73.5	100	100	94	
		20	100	100	66	100	100	97	100	100	100	100	99.5	63.5	100	100	90	100	100	100	
		30	100	100	74.5	100	100	97.5	100	100	100	100	100	72.5	100	100	99	100	100	100	
	μ ₀ = 30	5	10	58.5	32	11.5	95	63	25.5	100	87.5	44.5	59	34	11	92	65.5	20	99	89	45.5
			20	90	57	15	99.5	93	41.5	100	100	74.5	89	55.5	16.5	100	91	40	100	99	71
			30	100	81	28.5	100	99.5	57	100	100	93	97.5	81.5	27.5	100	98.5	57.5	100	100	92
10		10	91	59	17	100	95	45	100	100	76	92.5	58.5	14.5	100	93.5	39.5	100	99.5	76	
		20	99.5	86.5	32.5	100	100	74	100	100	95	99.5	86	32.5	100	100	72	100	100	93	
		30	100	97	52	100	100	84	100	100	100	100	97.5	50.5	100	100	85.5	100	100	99.5	
20		10	100	90.5	36	100	100	80	100	100	95.5	100	92.5	33	100	100	78	100	100	97.5	
		20	100	98	56.5	100	100	93.5	100	100	100	100	100	63	100	100	93	100	100	100	
		30	100	100	76	100	100	100	100	100	100	100	100	73.5	100	100	99	100	100	100	
μ ₀ = 45		5	10	61	38	10	95.5	68.5	29	100	95	45.5	59.5	34	10	95	67.5	28.5	100	93.5	43.5
			20	90	58	19	100	94.5	39.5	100	100	77	90.5	60.5	18.5	100	92	37.5	100	100	74.5
			30	98.5	81	27	100	99.5	65	100	100	93.5	98.5	83.5	24	100	99.5	63	100	100	94
	10	10	91	59.5	20.5	100	96.5	49	100	100	78.5	91	60.5	15.5	100	97	45.5	100	100	76	
		20	100	87	36	100	100	71.5	100	100	94.5	99.5	89.5	37	100	100	73.5	100	100	95	
		30	100	98.5	49.5	100	100	86	100	100	100	100	99	49	100	100	89.5	100	100	100	
	20	10	100	93.5	38	100	100	82.5	100	100	100	100	91	33	100	100	80	100	100	99	
		20	100	100	64.5	100	100	97.5	100	100	100	100	100	65.5	100	100	95	100	100	100	
		30	100	100	76	100	100	100	100	100	100	100	100	79	100	100	99.5	100	100	100	

ICC, intra-cluster correlation; TBA, transmission blocking activity; n, number of participants; m, number of mosquitos dissected; μ₀ baseline oocyst density; τ, the threshold at which we wish to test that the anticipated TBA exceeds.

such as feeding protocol (e.g. direct skin versus membrane feeding, duration of feeding, type of artificial membrane), donor characteristics (e.g. minimum parasite or gametocyte density) and mosquito characteristics (e.g. receptivity and survival rate), that lead to site-specific differences in baseline oocyst density, proportion of infected mosquitos or number of mosquitos available for dissection (38, 48). As illustrated in the current analysis, there can even be considerable variation between experiments conducted at the same study site with the same procedures and inclusion criteria (Figure 1) (48, 55). It is thus imperative to obtain site-specific baseline estimates of infectivity in pilot experiments prior to designing transmission-blocking intervention trials. For studies in natural gametocyte carriers, one approach is to determine in pilot experiments what percentage infected mosquitos can be achieved with the enrolment criteria of the envisaged clinical trial. We explored the number of gametocyte carriers that should be included in such pilot experiments by randomly selecting participants from our study population. Including a minimum of 40 donors allowed us to approximate the ‘true’ mosquito infection prevalence and intra-cluster correlation with sufficient precision to allow power calculations. An alternative or complementing approach would be to test whether the association between gametocyte density and mosquito infection rates in the envisaged study population follows that of a recent

multi-site study (48) and subsequently decide what a minimum gametocyte density should be for study participants to be enrolled in the study. Using stringent eligibility criteria can increase the pre-intervention proportion of infected mosquitos, resulting in an increased efficiency of the trial. As an example, using the reference values of the transmission blocking intervention trial described above (i.e. intra-cluster correlation = 0.52, anticipated TBA = 88%, number of participants = 20, number of dissected mosquitos per experiment = 40, threshold value of TBA = 80%), by only including participants with a minimal gametocyte density of 100 gametocytes/μL, the baseline proportion of infected mosquitos can increase from 17.0% to 34.6%, resulting in a power increase from 82.5% to 92%. Whilst it may be challenging to recruit these rare high-density gametocyte carriers, it will increase study power.

Our analyses emphasize the value of a site-adaptable tool to analyze data and make power calculations for trials with transmission-blocking interventions. The high variability in baseline data highlights that use of site-specific baseline data is strongly recommended for obtaining reference values to enter in the power calculator, instead of using the preset reference values or power estimations as presented in Tables 1, 2, that are based on the datasets described in this manuscript.

An important consideration to consider when using the app is that the power calculations are based on finding TRA or TBA above a certain threshold within study arms or within a total

study population, but not on the comparison of transmission blocking efficacy between two intervention arms. Although the app is not designed for this, the data analysis tool does offer the opportunity for some alternative analyses. If the number of infectious individuals (i.e. the number of individuals infecting at least one mosquito) is a preferred outcome instead of TBA or TRA, the analysis tool can be used by generating a dataset with only one fictive dissected mosquito per individual and entering 0 for non-infectious and 1 for infectious individuals in the column for number of infectious mosquitos. Additionally, the analysis tool could be used for other paired assessments of infectivity (for example the relative transmission of a primary vivax infection compared to a recrudescence infection).

In conclusion, we have developed a tool for analysis and power calculation of transmission blocking intervention trials that is accessible on https://bousema-lab.shinyapps.io/transmission_sample_size/. This supports the inclusion of functional mosquito feeding assays to assess intervention efficacy in early phase trials and thereby maximize their informativeness. This may accelerate the clinical development of transmission blocking interventions. At present, mosquito feeding assays remain a surrogate endpoint for public health impact that requires confirmation; predicting the association between intervention efficacy in terms of reductions in the proportion of infected mosquitos and the public health impact at population level is a high priority.

DATA AVAILABILITY STATEMENT

Datasets used to demonstrate the utility of the app are available upon request to the corresponding author. Requests to access these datasets should be directed to teun.bousema@radboudumc.nl.

ETHICS STATEMENT

All trials in Mali received ethics approval by the Ethics Committee of the Faculty of Medicine, Pharmacy, and

Dentistry of the University of Science, Techniques, and Technologies of Bamako (Bamako, Mali), and the Research Ethics Committee of the London School of Hygiene & Tropical Medicine (London, UK). The trial in the Netherlands received approval from the Arnhem-Nijmegen Committee on Research Involving Humans. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

JR and MA analyzed the data and drafted the first version of the manuscript; JB, AD, CD, and WS contributed data and assisted in data analysis and interpretation and in the drafting of the manuscript. TB conceived the study, contributed to data analysis, and drafted the first version of the manuscript. JR, MA and TB designed the app and JR programmed the app. All authors contributed to manuscript revision, read, and approved the submitted version.

FUNDING

This work was supported by the Gates Foundation (INV-002098). JB received support from the UK Medical Research Council (MRC) and the UK Department for International Development (DFID; MR/K012126/1) under the MRC-DFID Concordat agreement and as part of the EDCTP2 program supported by the EU. TB is supported by a European Research Council Consolidator Grant (ERC-CoG 864180; QUANTUM). TB and MA are further supported by an AMMODO Science Award (2019).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fimmu.2022.899615/full#supplementary-material>

REFERENCES

1. Organisation WH. *World Malaria Report 2021*. Geneva: World Health Organization (2021).
2. Rabinovich RN, Drakeley C, Djimde AA, Hall BF, Hay SI, Hemingway J, et al. Malera: An Updated Research Agenda for Malaria Elimination and Eradication. *PLoS Med* (2017) 14(11):e1002456. doi: 10.1371/journal.pmed.1002456
3. Sowunmi A, Fateye BA. Changes in Plasmodium Falciparum Gametocytaemia in Children With Chloroquine-Sensitive Asexual Infections. *Parasite* (2003) 10(4):363–9. doi: 10.1051/parasite/2003104363
4. Dicko A, Roh ME, Diawara H, Mahamar A, Soumare HM, Lanke K, et al. Efficacy and Safety of Primaquine and Methylene Blue for Prevention of Plasmodium Falciparum Transmission in Mali: A Phase 2, Single-Blind, Randomised Controlled Trial. *Lancet Infect Dis* (2018) 18(6):627–39. doi: 10.1016/S1473-3099(18)30044-6
5. Vanaerschot M, Lucantoni L, Li T, Combrinck JM, Ruecker A, Kumar TRS, et al. Hexahydroquinolines Are Antimalarial Candidates With Potent Blood-Stage and Transmission-Blocking Activity. *Nat Microbiol* (2017) 2(10):1403–14. doi: 10.1038/s41564-017-0007-4
6. Singh SK, Thrane S, Chourasia BK, Teelen K, Graumans W, Stoter R, et al. Pfs230 and Pfs48/45 Fusion Proteins Elicit Strong Transmission-Blocking Antibody Responses Against Plasmodium Falciparum. *Front Immunol* (2019) 10:1256(1256). doi: 10.3389/fimmu.2019.01256
7. Chichester JA, Green BJ, Jones RM, Shoji Y, Miura K, Long CA, et al. Safety and Immunogenicity of a Plant-Produced Pfs25 Virus-Like Particle as a Transmission Blocking Vaccine Against Malaria: A Phase 1 Dose-Escalation Study in Healthy Adults. *Vaccine* (2018) 36(39):5865–71. doi: 10.1016/j.vaccine.2018.08.033
8. Armistead JS, Morlais I, Mathias DK, Jardim JG, Joy J, Fridman A, et al. Antibodies to a Single, Conserved Epitope in Anopheles Apn1 Inhibit Universal Transmission of Plasmodium Falciparum and Plasmodium Vivax Malaria. *Infect Immun* (2014) 82(2):818–29. doi: 10.1128/IAI.01222-13
9. Coelho CH, Jore MM, Canepa GE, Barillas-Mury C, Bousema T, Duffy PE. Antibody Therapy Goes to Insects: Monoclonal Antibodies Can Block Plasmodium Transmission to Mosquitoes. *Trends Parasitol* (2020) 36(11):880–3. doi: 10.1016/j.pt.2020.08.009
10. Coelho CH, Tang WK, Burkhardt M, Galson JD, Muratova O, Salinas ND, et al. A Human Monoclonal Antibody Blocks Malaria Transmission and

- Defines a Highly Conserved Neutralizing Epitope on Gametes. *Nat Commun* (2021) 12(1):1750. doi: 10.1038/s41467-021-21955-1
11. Nunes JK, Woods C, Carter T, Raphael T, Morin MJ, Diallo D, et al. Development of a Transmission-Blocking Malaria Vaccine: Progress, Challenges, and the Path Forward. *Vaccine* (2014) 32(43):5531–9. doi: 10.1016/j.vaccine.2014.07.030
 12. Alkema M, Reuling IJ, de Jong GM, Lanke K, Coffeng LE, van Gemert GJ, et al. A Randomized Clinical Trial to Compare P. Falciparum Gametocytaemia and Infectivity Following Blood-Stage or Mosquito Bite Induced Controlled Malaria Infection. *J Infect Dis* (2020) 224:1257–65. doi: 10.1093/infdis/jiaa157
 13. Collins KA, Wang CY, Adams M, Mitchell H, Rampton M, Elliott S, et al. A Controlled Human Malaria Infection Model Enabling Evaluation of Transmission-Blocking Interventions. *J Clin Invest* (2018) 128(4):1551–62. doi: 10.1172/jci98012
 14. Reuling IJ, van de Schans LA, Coffeng LE, Lanke K, Meerstein-Kessel L, Graumans W, et al. A Randomized Feasibility Trial Comparing Four Antimalarial Drug Regimens to Induce Plasmodium Falciparum Gametocytemia in the Controlled Human Malaria Infection Model. *eLife* (2018) 7:e31549. doi: 10.7554/eLife.31549
 15. Bousema T, Drakeley C. Determinants of Malaria Transmission at the Population Level. *Cold Spring Harb Perspect Med* (2017) 7:a025510. doi: 10.1101/cshperspect.a025510
 16. Churcher TS, Sinden RE, Edwards NJ, Poulton ID, Rampling TW, Brock PM, et al. Probability of Transmission of Malaria From Mosquito to Human Is Regulated by Mosquito Parasite Density in Naïve and Vaccinated Hosts. *PLoS Pathog* (2017) 13(1):e1006108. doi: 10.1371/journal.ppat.1006108
 17. Aleshnick M, Ganusov VV, Nasir G, Yenokyan G, Sillis P. Experimental Determination of the Force of Malaria Infection Reveals a Non-Linear Relationship to Mosquito Sporozoite Loads. *PLoS Pathog* (2020) 16(5): e1008181. doi: 10.1371/journal.ppat.1008181
 18. Graumans W, Jacobs E, Bousema T, Sillis P. When Is a Plasmodium-Infected Mosquito an Infectious Mosquito? *Trends Parasitol* (2020) 36(8):705–16. doi: 10.1016/j.pt.2020.05.011
 19. Stone WJR, Eldering M, van Gemert G-J, Lanke KHW, Grignard L, van de Vegte-Bolmer MG, et al. The Relevance and Applicability of Oocyst Prevalence as a Read-Out for Mosquito Feeding Assays. *Sci Rep* (2013) 3:3418. doi: 10.1038/srep03418
 20. Miura K, Stone WJR, Koolen KM, Deng B, Zhou L, van Gemert G-J, et al. An Inter-Laboratory Comparison of Standard Membrane-Feeding Assays for Evaluation of Malaria Transmission-Blocking Vaccines. *Malaria J* (2016) 15(1):463. doi: 10.1186/s12936-016-1515-z
 21. Churcher TS, Blagborough AM, Delves M, Ramakrishnan C, Kapulu MC, Williams AR, et al. Measuring the Blockade of Malaria Transmission—an Analysis of the Standard Membrane Feeding Assay. *Int J Parasitol* (2012) 42(11):1037–44. doi: 10.1016/j.ijpara.2012.09.002
 22. Billingsley PF, Medley GF, Charlwood D, Sinden RE. Relationship Between Prevalence and Intensity of Plasmodium Falciparum Infection in Natural Populations of Anopheles Mosquitoes. *Am J Trop Med Hyg* (1994) 51(3):260–70. doi: 10.4269/ajtmh.1994.51.260
 23. Medley GF, Sinden RE, Fleck S, Billingsley PF, Tirawanchai N, Rodriguez MH. Heterogeneity in Patterns of Malarial Oocyst Infections in the Mosquito Vector. *Parasitology* (1993) 106(Pt 5):441–9. doi: 10.1017/s0031182000076721
 24. Blagborough AM, Churcher TS, Upton LM, Ghani AC, Gething PW, Sinden RE. Transmission-Blocking Interventions Eliminate Malaria From Laboratory Populations. *Nat Commun* (2013) 4(1):1812. doi: 10.1038/ncomms2840
 25. Dicko A, Brown JM, Diawara H, Baber I, Mahamar A, Soumare HM, et al. Primaquine to Reduce Transmission of Plasmodium Falciparum Malaria in Mali: A Single-Blind, Dose-Ranging, Adaptive Randomised Phase 2 Trial. *Lancet Infect Dis* (2016) 16(6):674–84. doi: 10.1016/s1473-3099(15)00479-x
 26. Stone W, Mahamar A, Sanogo K, Sinaba Y, Niambele SM, Sacko A, et al. Pyronaridine-Artesunate or Dihydroartemisinin-Piperaquine Combined With Single Low-Dose Primaquine to Prevent Plasmodium Falciparum Malaria Transmission in Ouélessébougou, Mali: A Four-Arm, Single-Blind, Phase 2/3, Randomised Trial. *Lancet Microbe* (2022) 3(1):e41–51. doi: 10.1016/s2666-5247(21)00192-0
 27. Stone W, Mahamar A, Smit MJ, Sanogo K, Sinaba Y, Niambele SM, et al. Single Low-Dose Tafenoquine Combined With Dihydroartemisinin-Piperaquine to Reduce Plasmodium Falciparum Transmission in Ouelessebougou, Mali: A Phase 2, Single-Blind, Randomised Clinical Trial. [Accepted publication] *Lancet Microbe* (2022) 3:e336–47. doi: 10.2139/ssrn.3903938
 28. Saul A. Efficacy Model for Mosquito Stage Transmission Blocking Vaccines for Malaria. *Parasitology* (2008) 135(13):1497–506. doi: 10.1017/s0031182008000280
 29. malERA CGoV. A Research Agenda for Malaria Eradication: Vaccines. *PLoS Med* (2011) 8(1):e1000398–e. doi: 10.1371/journal.pmed.1000398
 30. van der Boor SC, Smit M, van Beek SW, Ramjith J, Teelen K, van de Vegte-Bolmer M, et al. Safety, Tolerability and Plasmodium Falciparum Transmission-Reducing Activity of Monoclonal Antibody Tb31f: An Open-Label, First-In-Human, Trial in Healthy Malaria-Naïve Adults. (2022). doi: 10.2139/ssrn.4054462
 31. de Graaf H, Payne RO, Taylor I, Miura K, Long CA, Elias SC, et al. Safety and Immunogenicity of Chad63/Mva Pfs25-Imx313 in a Phase I First-In-Human Trial. *Front Immunol* (2021) 12:694759. doi: 10.3389/fimmu.2021.694759
 32. Wu Y, Ellis RD, Shaffer D, Fontes E, Malkin EM, Mahanty S, et al. Phase 1 Trial of Malaria Transmission Blocking Vaccine Candidates Pfs25 and Pvs25 Formulated With Montanide Isa 51. *PLoS One* (2008) 3(7):e2636. doi: 10.1371/journal.pone.0002636
 33. Sawa P, Shekalaghe SA, Drakeley CJ, Sutherland CJ, Mweresa CK, Baidjoe AY, et al. Malaria Transmission After Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine: A Randomised Trial. *J Infect Dis* (2013) 207(11):1637–45. doi: 10.1093/infdis/jit077
 34. Gonçalves BP, Tiono AB, Ouédraogo A, Guelbéogo WM, Bradley J, Nebie I, et al. Single Low Dose Primaquine to Reduce Gametocyte Carriage and Plasmodium Falciparum Transmission After Artemether-Lumefantrine in Children With Asymptomatic Infection: A Randomised, Double-Blind, Placebo-Controlled Trial. *BMC Med* (2016) 14:40. doi: 10.1186/s12916-016-0581-y
 35. Vantaux A, Samreth R, Piv E, Khim N, Kim S, Berne L, et al. Contribution to Malaria Transmission of Symptomatic and Asymptomatic Parasite Carriers in Cambodia. *J Infect Dis* (2018) 217(10):1561–8. doi: 10.1093/infdis/jiy060
 36. Sauerwein RW, Bousema T. Transmission Blocking Malaria Vaccines: Assays and Candidates in Clinical Development. *Vaccine* (2015) 33(52):7476–82. doi: 10.1016/j.vaccine.2015.08.073
 37. van der Kolk M, De Vlas SJ, Saul A, van de Vegte-Bolmer M, Eling WM, Sauerwein RW. Evaluation of the Standard Membrane Feeding Assay (Smfa) for the Determination of Malaria Transmission-Reducing Activity Using Empirical Data. *Parasitology* (2005) 130(Pt 1):13–22. doi: 10.1017/s0031182004006067
 38. Bousema T, Dinglasan RR, Morlais I, Gouagna LC, van Warmerdam T, Awono-Ambene PH, et al. Mosquito Feeding Assays to Determine the Infectiousness of Naturally Infected Plasmodium Falciparum Gametocyte Carriers. *PLoS One* (2012) 7(8):e42821. doi: 10.1371/journal.pone.0042821
 39. Team RC. *R: A Language and Environment for Statistical Computing*. Vienna, Austria: R Foundation for Statistical Computing (2021). Available at: <https://www.R-project.org/>.
 40. Team R. *Rstudio: Integrated Development Environment for R*. Boston, MA: RStudio, PBC (2021). Available at: <http://www.rstudio.com/>.
 41. Wood SN. Fast Stable Restricted Maximum Likelihood and Marginal Likelihood Estimation of Semiparametric Generalized Linear Models. *J R Stat Soc: Ser B (Statistical Methodology)* (2011) 73(1):3–36. doi: 10.1111/j.1467-9868.2010.00749.x
 42. Wood SN. *Generalized Additive Models - an Introduction With R. 2nd Edition* Vol. 3. New York: Chapman and Hall/CRC (2017). p. 496.
 43. Chang W, Cheng J, Allaire J, Sievert C, Schloerke B, Xie Y, et al. Shiny: Web Application Framework for R. *R Package Version 1.7.1* (2021).
 44. Churcher TS, Bousema T, Walker M, Drakeley C, Schneider P, Ouedraogo AL, et al. Predicting Mosquito Infection From Plasmodium Falciparum Gametocyte Density and Estimating the Reservoir of Infection. *eLife* (2013) 2:e00626. doi: 10.7554/eLife.00626
 45. Barry A, Bradley J, Stone W, Guelbeogo MW, Lanke K, Ouedraogo A, et al. Higher Gametocyte Production and Mosquito Infectivity in Chronic Compared to Incident Plasmodium Falciparum Infections. *Nat Commun* (2021) 12(1):2443. doi: 10.1038/s41467-021-22573-7
 46. Jeffery GM, Eyles DE. Infectivity to Mosquitoes of Plasmodium Falciparum as Related to Gametocyte Density and Duration of Infection. *Am J Trop Med Hyg* (1955) 4(5):781–9. doi: 10.4269/ajtmh.1955.4.781

47. Graves PM, Burkot TR, Carter R, Cattani JA, Lagog M, Parker J, et al. Measurement of Malarial Infectivity of Human Populations to Mosquitoes in the Madang Area, Papua New Guinea. *Parasitology* (1988) 96(2):251–63. doi: 10.1017/S003118200005825X
48. Bradley J, Stone W, Da DF, Morlais I, Dicko A, Cohuet A, et al. Predicting the Likelihood and Intensity of Mosquito Infection From Sex Specific Plasmodium Falciparum Gametocyte Density. *eLife* (2018) 7:e34463. doi: 10.7554/eLife.34463
49. White NJ. Primaquine to Prevent Transmission of Falciparum Malaria. *Lancet Infect Dis* (2013) 13(2):175–81. doi: 10.1016/S1473-3099(12)70198-6
50. Baker DA, Stewart LB, Large JM, Bowyer PW, Ansell KH, Jiménez-Díaz MB, et al. A Potent Series Targeting the Malarial Cgmp-Dependent Protein Kinase Clears Infection and Blocks Transmission. *Nat Commun* (2017) 8(1):430. doi: 10.1038/s41467-017-00572-x
51. Schalkwijk J, Allman EL, Jansen PAM, de Vries LE, Verhoef MJ, Jackowski S, et al. Antimalarial Pantothenamide Metabolites Target Acetyl-Coenzyme A Biosynthesis in Plasmodium Falciparum. *Sci Trans Med* (2019) 11(510): eaas9917. doi: 10.1126/scitranslmed.aas9917
52. Miguel-Blanco C, Molina I, Bardera AI, Díaz B, de Las Heras L, Lozano S, et al. Hundreds of Dual-Stage Antimalarial Molecules Discovered by a Functional Gametocyte Screen. *Nat Commun* (2017) 8:15160. doi: 10.1038/ncomms15160
53. Duffy PE. Transmission-Blocking Vaccines: Harnessing Herd Immunity for Malaria Elimination. *Expert Rev Vaccines* (2021) 20(2):185–98. doi: 10.1080/14760584.2021.1878028
54. Miura K, Deng B, Tullo G, Diouf A, Moretz SE, Locke E, et al. Qualification of Standard Membrane-Feeding Assay With Plasmodium Falciparum Malaria and Potential Improvements for Future Assays. *PLoS One* (2013) 8(3):e57909. doi: 10.1371/journal.pone.0057909
55. van de Vegte-Bolmer M, Graumans W, Stoter R, van Gemert G-J, Sauerwein R, Collins KA, et al. A Portfolio of Geographically Distinct Laboratory-Adapted Plasmodium Falciparum Clones With Consistent Infection Rates in Anopheles Mosquitoes. *Malaria J* (2021) 20(1):381. doi: 10.1186/s12936-021-03912-x

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Ramjith, Alkema, Bradley, Dicko, Drakeley, Stone and Bousema. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.